134 related articles for article (PubMed ID: 31050072)
1. Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1.
Yong L; Ma Y; Liang C; He G; Zhao Z; Yang C; Hai B; Pan X; Liu Z; Liu X
Phytother Res; 2019 Jul; 33(7):1837-1850. PubMed ID: 31050072
[TBL] [Abstract][Full Text] [Related]
2. Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway.
Yong L; Ma Y; Zhu B; Liu X; Wang P; Liang C; He G; Zhao Z; Liu Z; Liu X
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1009-1020. PubMed ID: 30267330
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/β-catenin signaling pathway.
Ma Y; Zhu B; Liu X; Yu H; Yong L; Liu X; Shao J; Liu Z
J Exp Clin Cancer Res; 2015 Oct; 34():115. PubMed ID: 26444270
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
[TBL] [Abstract][Full Text] [Related]
5. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells.
Yuan JM; Li XD; Liu ZY; Hou GQ; Kang JH; Huang DY; Du SX
Asian Pac J Cancer Prev; 2011; 12(12):3465-9. PubMed ID: 22471498
[TBL] [Abstract][Full Text] [Related]
7. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
Jandial DD; Farshchi-Heydari S; Larson CA; Elliott GI; Wrasidlo WJ; Howell SB
Clin Cancer Res; 2009 Jan; 15(2):553-60. PubMed ID: 19147760
[TBL] [Abstract][Full Text] [Related]
8. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Jaehde U
J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
[TBL] [Abstract][Full Text] [Related]
9. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop.
Zhang W; Shi H; Chen C; Ren K; Xu Y; Liu X; He L
Phytomedicine; 2018 Sep; 48():51-61. PubMed ID: 30195880
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
11. [Lethal effects of nanoliposome encapsulated cisplatin on Saos-2 cells and its distribution in nude mice bearing human].
Wang GW; Guo W; Tang XD; Peng CL; Zhao H
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):525-30. PubMed ID: 19829667
[TBL] [Abstract][Full Text] [Related]
12. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
Howell SB; Safaei R; Larson CA; Sailor MJ
Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
[TBL] [Abstract][Full Text] [Related]
13. miR-214 modulates cisplatin sensitivity of osteosarcoma cells through regulation of anaerobic glycolysis.
Song YD; Li DD; Guan Y; Wang YL; Zheng J
Cell Mol Biol (Noisy-le-grand); 2017 Sep; 63(9):75-79. PubMed ID: 28980925
[TBL] [Abstract][Full Text] [Related]
14. Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells.
Zhu W; Mao X; Wang W; Chen Y; Li D; Li H; Dou P
Pharmazie; 2018 Feb; 73(2):80-86. PubMed ID: 29442009
[TBL] [Abstract][Full Text] [Related]
15. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
[TBL] [Abstract][Full Text] [Related]
16. Mxd1 mediates hypoxia-induced cisplatin resistance in osteosarcoma cells by repression of the PTEN tumor suppressor gene.
Zheng D; Wu W; Dong N; Jiang X; Xu J; Zhan X; Zhang Z; Hu Z
Mol Carcinog; 2017 Oct; 56(10):2234-2244. PubMed ID: 28543796
[TBL] [Abstract][Full Text] [Related]
17. Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.
Safaei R; Maktabi MH; Blair BG; Larson CA; Howell SB
J Inorg Biochem; 2009 Mar; 103(3):333-41. PubMed ID: 19124158
[TBL] [Abstract][Full Text] [Related]
18. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
Blair BG; Larson CA; Adams PL; Abada PB; Safaei R; Howell SB
Mol Pharmacol; 2010 Jun; 77(6):912-21. PubMed ID: 20194531
[TBL] [Abstract][Full Text] [Related]
19. A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment.
Landon CD; Benjamin SE; Ashcraft KA; Dewhirst MW
Int J Hyperthermia; 2013 Sep; 29(6):528-38. PubMed ID: 23879689
[TBL] [Abstract][Full Text] [Related]
20. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.
Pasello M; Michelacci F; Scionti I; Hattinger CM; Zuntini M; Caccuri AM; Scotlandi K; Picci P; Serra M
Cancer Res; 2008 Aug; 68(16):6661-8. PubMed ID: 18701490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
